NSE, BSE give in-principle approval to 8,05,35,651-share preferential issue via share swap
Anlon Healthcare has received 'In-Principle' approval from NSE and BSE for the proposed preferential issue of ~8.05 crore equity shares of Rs. 2/- each through a share swap.
By ScoutQuest · · 2 min read
- Proposed equity shares
- 8,05,35,651
- Face value per share
- Rs. 2/-
- Approval letter date
- 28/10/2026
What was announced
Anlon Healthcare has received 'In-Principle' approval from the National Stock Exchange of India Limited and BSE Limited for the proposed issuance of ~8.05 crore equity shares of Rs. 2/- each, pursuant to a proposed share swap, on a preferential basis. The company has placed on record the letters received from NSE and BSE, both dated 28/10/2026.
What 'In-Principle' approval means
- It is a clearance from the stock exchanges that allows the proposed preferential issue to go ahead to its next steps.
- It does not mean the shares have been issued. The update describes the issuance as proposed.
- The issuance is to be made under Chapter V of the SEBI (ICDR) Regulations, 2018.
Preferential issue and share swap, in simple terms
- A preferential issue means shares are allotted to specific identified persons rather than to the general public.
- A share swap means the consideration for these shares is shares of another entity, not cash, as stated in the update.
Figures to note
- Number of equity shares proposed to be issued: 8,05,35,651
- Face value of each such equity share: Rs. 2/-
- The shares are proposed to be issued on a preferential basis through a share swap.
What an investor can track from here
- The word 'proposed' matters: the issuance is yet to take place, and the in-principle approval is a step along the way.
- The share count, ~8.05 crore equity shares of Rs. 2/- each, is the figure to keep in view when the allotment is taken up.
- In a share swap, the consideration is shares of another entity, so what is being exchanged forms the core of the transaction.
The announcement itself is an update on the approval stage of a proposed transaction; the terms of the swap and the allotment are separate steps that would follow.
Also from Anlon Healthcare
Anlon Healthcare Q2 FY27 revenue doubles to INR 10,561.0 lacs as it builds integrated pharma platform
30 Oct 2026
Board approves unaudited Q2 results; auditor's review conclusion unmodified
29 Oct 2026
Anlon Healthcare to hold Q2 & H1 FY27 earnings call on 3 November 2026
26 Oct 2026
More numbers
- Equity shares proposed to be issued8,05,35,651
- Face value per equity shareRs. 2/-
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.